WebMD

Cosentyx: FDA Approves Biologic Under-the-Skin Shot for Teens With Moderate-to-Severe Hidradenitis Suppurativa

What Is Cosentyx, and Why Does It Matter? Cosentyx (secukinumab) is a fully human biologic medicine that targets and blocks interleukin‑17A (IL‑17A), a naturally occurring protein in the body that ...
The Trentonian

Novartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis

EAST HANOVER, N.J., June 1, 2021 /PRNewswire/ — Novartis, a leader in immuno-dermatology and rheumatology, today announced the U.S. Food and Drug Administration (FDA) has approved Cosentyx (R) ...
AOL

Which Medicare Part covers Cosentyx?

The Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) injections for treating various inflammatory conditions in adults and, in some cases, children. Cosentyx may treat moderate ...
Monthly Prescribing Reference

Cosentyx Approved for Pediatric Plaque Psoriasis

The approval was based on data from two phase 3 trials that evaluated the use of Cosentyx in patients 6 to 18 years of age with severe plaque psoriasis who were candidates for systemic therapy. The ...
The Trentonian

Novartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis

Getting your Trinity Audio player ready... The approved pediatric dosing for Cosentyx is 75 mg or 150 mg depending on the child’s weight at the time of dosing and is administered by subcutaneous ...